Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15683072 | 0.86 | DHFR (0.40) | DHFRMEN1KMT2AHSP90AA1ADORA2A | |
| SCHEMBL4264063 | 0.85 | DHFR (0.43) | DHFRMEN1KMT2AHSP90AA1ADORA2A | |
| SCHEMBL6679657 | 0.81 | DHFR (0.35) | DHFRNQO2PDPK1 | |
| SCHEMBL6679667 | 0.80 | NQO2 (0.36) | DHFRNQO2PDPK1 | |
| SCHEMBL6371452 | 0.79 | NQO2 (0.39) | DHFRKMT2ANQO2PDPK1TLR8 | |
| SCHEMBL4266090 | 0.79 | MEN1 (0.40) | DHFRMEN1KMT2AHSP90AA1ADORA2A | |
| SCHEMBL4265979 | 0.77 | AMY1A (0.36) | DHFRADORA2A | |
| SCHEMBL1517137 | 0.75 | LCK (0.59) | DHFRMEN1KMT2AHSP90AA1ADORA2A | |
| SCHEMBL4267547 | 0.73 | PDGFRB (0.43) | DHFRMEN1KMT2AADORA2AADORA1 | |
| SCHEMBL29973127 | 0.72 | MEN1 (0.45) | MEN1KMT2AS1PR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1809614-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | DHFR 1676/4885MEN1 4284/4885KMT2A 1819/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | DHFR 1676/4885MEN1 4284/4885KMT2A 1819/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | DHFR 1676/4885MEN1 4284/4885KMT2A 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.